Apo2L/TRAIL killing of tumour cells and the role of Inhibitor of Apoptosis proteins

Apo2L/TRAIL对肿瘤细胞的杀伤作用及凋亡抑制蛋白的作用

• 批准号: nhmrc : 433013
• 负责人: Prof John Silke
• 金额: $ 26.03万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/apo2ltrail-killing-tumour-apoptosis-proteins/95640
• 关键词: Apo2L; TRAIL; killing; tumour; cells

Melanomas and Gliomas are tumour types that respond poorly to current treatments. Current treatments are not only sometimes ineffective, but also unpleasant and may cause co-lateral damage. We will test 2 new targetted anti-cancer treatments, that so far appear to have minor side effects in small animal models, on these difficult to treat tumour types to see if and how they kill them. We also want to know whether these independent treatments can work together to kill tumours more effectively. Although we will not personally test these drugs in clinical settings, these drugs or similar are currently in preclinical and clinical trials. This means that understanding how these drugs function is of paramount importance and may result in better clinical trials and possibly more rapid acceptance of the use of these drugs in patients.

黑色素瘤和胶质瘤是对当前治疗反应不佳的肿瘤类型。目前的治疗方法不仅有时无效，而且令人不快，并可能导致共同侧向损伤。我们将在这些难以治疗的肿瘤类型上测试两种新的靶向抗癌疗法，看看它们是否以及如何杀死它们。到目前为止，这些疗法在小动物模型上似乎有轻微的副作用。我们还想知道这些独立的治疗方法是否可以共同作用，更有效地杀死肿瘤。虽然我们不会在临床环境中亲自测试这些药物，但这些药物或类似药物目前正在进行临床前和临床试验。这意味着了解这些药物如何发挥作用至关重要，可能会导致更好的临床试验，并可能更快地接受患者使用这些药物。